Sight Sciences, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Sight Sciences reported Q3 2026 revenue of $24.9 million (up 25% YoY from $19.9M), with Interventional Glaucoma revenue of $21.0 million (+7% YoY) and Interventional Dry Eye revenue of $3.9 million (up 1,850% YoY from $0.2M). The company raised full-year 2026 revenue guidance to $92–93 million (19–20% growth) from prior guidance of $88–92 million, and increased IDE revenue guidance to ~$12 million from $9–11 million. Cash burn improved 74% to $2.4 million in Q3 2026 versus $9.1 million in Q3 2025. Net loss improved to $6.8 million from $8.2 million YoY.
Why this rating
Strong revenue growth (25%), margin expansion in IDE (79%), rapid cash burn reduction (74%), and raised guidance demonstrate execution and market traction. IDE scaling (1,850% YoY) and OMNI Ultra launch are material catalysts. Event represents meaningful upside revision relative to company's ~$154M market cap but not transformational yet.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.